Labeling Stem Cells with a New Hybrid Bismuth/Carbon Nanotube Contrast Agent for X-Ray Imaging

In Situ Stabilization of Bi Nanoparticles into the Nanopores of Modified Montmorillonite: Efficient Heterogeneous Catalysts for Reduction of 4-Nitrophenol

Here, we report the in situ generation of Bi nanoparticles (BiNPs) into a nanoporous matrix by impregnation of bismuth chloride and subsequent reduction with sodium borohydride. The nanoporous matrix was created by acid activation of natural montmorillonite clay under controlled conditions with the aim that it may serve as a host for BiNPs. The characterization of stabilized BiNPs was done by using Fourier-transform infrared (FTIR), powder X-ray diffraction (PXRD), X-ray photoelectron spectroscopy (XPS), thermogravimetric analysis (TGA), transmission electron microscopy (TEM), and field emission scanning electron microscopy-energy dispersive X-ray (FESEM-EDX) techniques. The TEM study reveals that the BiNPs with an average particle size of 7.16 nm are well-distributed on the surface of the acid-activated montmorillonite clay. The synthesized BiNPs exhibited excellent catalytic activity for the degradation of 4-nitrophenol (4-NP) in aqueous medium with remarkable results. The degradation of 4-NP to 4-aminophenol (4-AP) at 25 °C, in the presence of sodium borohydride, brought about almost 100% conversion in 6 min with a rate constant of 0.20098 s-1 that follows the pseudo-first-order kinetics.

Bismuth-based nanoparticles impair adipogenic differentiation of human adipose-derived mesenchymal stem cells

Bismuth-based nanoparticles (BiNPs) have attracted attention for their potential biomedical applications. However, there is a lack of information concerning their interaction with biological systems. In this study, it was investigated the effect of physically synthesized BiNPs to human adipose-derived stem cells (ADSCs). We first evaluated the influence of BiNPs on cell viability, cell morphology, mitochondrial function and cell proliferation. Further, the impact of BiNPs on adipogenic differentiation was also explored. Cytotoxicity assays have demonstrated that BiNPs did not reduce relative cell viability of ADSC except at the highest tested concentration (345 μg/ml). Analysis of cell morphology performed by transmission electron microscopy confirmed that BiNPs induced cell damage only at a high concentration (302.24 μg/ml), equivalent to IC₅₀ concentration. Moreover, BiNPs exposure increased the expression of the cell proliferation marker Ki-67 and the incorporation of the thymidine analogue EdU into cell DNA, suggesting that these nanoparticles could be stimulating ADSC proliferation. BiNPs also increased the mitochondrial membrane potential. Furthermore, BiNPs reduced ADSC adipogenic differentiation as measured by lipid droplet accumulation and mRNA expression levels of the specific adipogenesis biomarkers PPARγ, C/EPBɑ and FABP4. Thus, BiNPs affect the nonspecific (viability, proliferation and mitochondrial activity) and specific (adipogenesis) cellular mechanisms of ADSCs.

Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade

In recent years, due to the shortcomings of conventional chemotherapy, such as poor bioavailability, low treatment index, and unclear side effects, the focus of cancer research has shifted to new nanocarriers of chemotherapeutic drugs. By using biodegradable materials, nanocarriers generally have the advantages of good biocompatibility, low side effects, targeting, controlled release profile, and improved efficacy. More to the point, nanocarrier based anti-cancer drug delivery systems clearly show the potential to overcome the problems associated with conventional chemotherapy. In order to promote the in-depth research and development in this field, we herein summarized and analyzed various nanocarrier based drug delivery systems for cancer therapy, including the concepts, types, characteristics, and preparation methods. The active and passive targeting mechanisms of cancer therapy were also included, along with a brief introduction of the research progress of nanocarriers used for anti-cancer drug delivery in the past decade.

Theranostic Applications of Nanostructured Silicate-Substituted Hydroxyapatite Codoped with Eu3+ and Bi3+ Ions-A Novel Strategy for Bone Regeneration

In this paper, nanocrystalline silicate-substituted hydroxyapatites (nSi-HAps) codoped with Eu³⁺ were functionalized with Bi³⁺ ions. Biomaterials were synthesized using a microwave-assisted hydrothermal method and heat-treated at 700 °C. The concentration of Eu³⁺ ions was established at 1 mol %, and the concentration of Bi³⁺ was in the range of 0.5-2 mol %. The physicochemical properties of the obtained biomaterials were determined using previously established methods, including X-ray powder diffraction, scanning electron microscopy techniques, and IR spectroscopy. Particle sizes obtained in this study were in the range of 22-65 nm, which was established by the Rietveld method. The luminescence properties of the Eu³⁺ ion-doped silicate-substituted apatite were recorded depending on the bismuth(III) concentration. The cytocompatibility of obtained biomaterials was tested using the model of mouse pre-osteoblasts cell line, that is, MC3T3-E1. We showed that the obtained biomaterials exerted anti-apoptotic effect, reducing the number of early and late apoptotic cells and decreasing caspase activity and reactive oxygen species accumulation. The transcripts levels of genes associated with apoptosis confirmed the anti-apoptotic effect of the biomaterials. Increased metabolic activity of MC3T3-E1 in cultures with biomaterials functionalized with Bi³⁺ ions has been observed. Moreover, the determined profile of osteogenic markers indicates that the obtained matrices, that is, Eu³⁺:nSi-HAp functionalized with Bi³⁺ ions, exert pro-osteogenic properties. The biological features of Eu³⁺:nSi-HAp modified with Bi³⁺ ions are highly desired in terms of functional tissue restoration and further efficient osteointegration.

Sensitive imaging of intact microvessels in vivo with synchrotron radiation

Early stages of diseases, including stroke, hypertension, angiogenesis of tumours, spinal cord injuries, etc., are closely associated with the lesions of microvasculature. Rodent models of human vascular diseases are extensively used for the preclinical investigation of the disease evolution and therapy with synchrotron radiation. Therefore, non-invasive and in vivo X-ray imaging with high sensitivity and clarity is desperately needed to visualize the microvessels in live-animal models. Contrast agent is essential for the in vivo X-ray imaging of vessels and angiomatous tissue. Because of the non-rigid motion of adjacent tissues, the short circulation time and the intermittent flow of contrast agents in vessels, it is a great challenge for the traditional X-ray imaging methods to achieve well defined images of microvessels in vivo. In this article, move contrast X-ray imaging (MCXI) based on high-brightness synchrotron radiation is developed to overcome the intrinsic defects in conventional methods. Experiments with live rodents demonstrate the practicability of the MCXI method for sensitive and intact imaging of microvessels in vivo.